Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center

American Journal of Preventive Cardiology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles